Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

GenSight Biologics S.A. (SIGHT) EUR0.025

Sell:€1.20 Buy:€1.23 Change: €0.13 (9.60%)
Market closed |  Prices as at close on 14 October 2019 | Switch to live prices |
Change: €0.13 (9.60%)
Market closed |  Prices as at close on 14 October 2019 | Switch to live prices |
Change: €0.13 (9.60%)
Market closed |  Prices as at close on 14 October 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Gensight Biologics SA is a France-based company, which specializes in the clinical-stage biotechnology and development of novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. The Company, through I ts integrated development platform, combines a gene therapy-based approach with core technology platforms of mitochondrial targeting sequence and optogenetics. It focuses on development of therapies for severe retinal diseases with the goal of preserving or restoring vision in patients with sight-threatening ophthalmic diseases. The Company provides two development programs with products, such as GS010 which aims at treating rare mitochondrial genetic disease, and GS030 which technology makes cells responsive to light. The products are designed to be administered in a single treatment to each eye by intravitreal or subretinal injection.

Contact details

74 rue du Faubourg Saint Antoine
+33 (1) 76217220

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
€38.67 million
Shares in issue:
28.99 million
Euronext Paris

Key personnel

  • Bernard Gilly
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Thomas Gidoin
    Chief Financial Officer
  • Jean-Philippe Combal
    Chief Operating Officer
  • Didier Pruneau
    Chief Scientific Officer
  • Magali Taiel
    Chief Medical Officer
  • Nitza Thomasson
    Head of Preclinical Development

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.